Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
Zhou, Zheng , Nath, Rajneesh , Černý, Jan , Wang, Hai-Lin, Zhang, Mei-Jie , Abdel‐Azim, Hisham , Agrawal, Vaibhav , Ahmed, Gulrayz , Al‐Homsi, A. Samer, Aljurf, Mahmoud , Battiwalla, Minocher, Byrne, Michael , Cahn, Jean‐Yves, Cairo, Mitchell S. , Choe, Hannah , Copelan, Edward A. , Damlaj, Moussab , DeFilipp, Zachariah , Farhadfar, Nosha , Foran, James M. , Freytes, César O. , Gul, Zartash , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Hossain, Nasheed , Inamoto, Yoshihiro , Isola, Luis , Jain, Tania , Kamble, Rammurti T., Khan, Muhammad , Kharfan‐Dabaja, Mohamed A. , Kekre, Natasha , Khera, Nandita , Litzow, Mark R. , Liu, Hongtao , Marks, David I. , Martino, Rodrigo , Mathews, Vikram , Mishra, Asmita , Murthy, Hemant S. , Nagler, Arnon , Nakamura, Ryotaro , Nathan, Sunita , Olin, Rebecca L. , Palmisiano, Neil , Patnaik, Mrinal M. , Pawarode, Attaphol , Politikos, Ioannis , Rizzieri, David A. , Seo, Sachiko , Shah, Nirav N. , Uy, Geoffrey L. , Verdonck, Leo F. , Wang, Youjin , Weisdorf, Daniel J. , Wirk, Baldeep , Saber, Wael , Hashmi, Shahrukh, Jain, Tania , Murthy, Hemant S , Weisdorf, Dan , Martino, Rodrigo , Liu, Hongtao , Mathews, Vikram , Uy, Geoffrey , Ahmed, Gulrayz , Zhang, Mei‐Jie , Alkhateeb, Hassan B. , Assal, Amer , Bacher, Ulrike , Bajel, Ashish R. , Bashir, Qaiser , Battiwalla, Minocher, Bhatt, Vijaya Raj , Cahn, Jean‐Yves , Cutler, Corey S. , Lima, Marcos de , Díaz, Miguel Ángel , Gerds, Aaron T. , Gergis, Usama , Grunwald, Michael R. , Hamadani, Mehdi , Hertzberg, Mark , Kebriaei, Partow , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Olsson, Richard F. , Patel, Sagar S. , Perales, Miguel‐Angel , Politikos, Ioannis , Popat, Uday R , Sandmaier, Brenda M , Savani, Bipin N. , Valcárcel, David , Waller, Edmund K. , Wong, Eric Y.L. , Yared, Jean A.

Mayo Clinic

Blood Advances | July 1, 2021 | Volume: 4 | Issue: 13 | Pages: 3180-3190

10.1182/bloodadvances.2019001266 | PMID 32663298 Get It

Abstract There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood and Marrow Transplant Research who received first RIC allo-transplant between 2001 and 2015 were studied. Patients were excluded if they received cord blood or identical twin transplant, total body irradiation in conditioning, or graft-versus-host disease (GVHD) prophylaxis with in vitro T-cell depletion. Primary outcome was overall survival (OS), secondary end points were leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and GVHD. Multivariate survival model was used with adjustment for patient, leukemia, and transplant-related factors. A total of 622 patients received FM and 791 received FB RIC. Compared with FB, the FM group had fewer transplant in complete remission (CR), fewer matched sibling donors, and less usage of anti-thymocyte globulin or alemtuzumab. More patients in the FM group received marrow grafts and had transplantation before 2005. OS was significantly lower within the first 3 months posttransplant in the FM group (hazard ratio [HR] = 1.82, P < .001), but was marginally superior beyond 3 months (HR = 0.87, P = .05). LFS was better with FM compared with FB (HR = 0.89, P = .05). NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P < .001). Long-term relapse was lower with FM (HR = 0.65, P < .001). Analysis restricted to patients with CR showed comparable results. In conclusion, compared with FB, the FM RIC showed a marginally superior long-term OS and LFS and a lower relapse rate. A lower OS early posttransplant within 3 months was largely the result of a higher early NRM.
Sex differences in type and occurrence of adverse reactions to opioid analgesics: a retrospective cohort study
Lopes, Guilherme S. , Bielinski, Suzette J. , Moyer, Ann M. , Jacobson, Debra J., Wang, Liwei , Jiang, Ruoxiang , Larson, Nicholas B. , Miller, Virginia M. , Zhu, Ye , Cavanaugh, Dana C., Bielinski, Suzette , St Sauver, Jennifer L , Larson, Nicholas B , Lopes, Guilherme S , Sauver, Jennifer L. St.

Mayo Clinic

BMJ Open | June 30, 2021 | Volume: 11 | Issue: 6 | Pages: e044157

10.1136/bmjopen-2020-044157 | PMID 34193479 Get It

Objectives Sex as a biological variable affects response to opioids. However, few reports describe the prevalence of specific adverse reactions to commonly prescribed opioids in men and women separately. A large cohort was used to investigate sex differences in type and occurrence of adverse reactions associated with use of codeine, tramadol, oxycodone and hydrocodone. Design Retrospective cohort study. Setting Participants in the Right Drug, Right Dose, Right Time (RIGHT) Study. Participants The medical records of 8457 participants in the RIGHT Study who received an opioid prescription between 1 January 2004 and 31 December 2017 were reviewed 61% women, 94% white, median age (Q1–Q3)=58 (47–66). Primary and secondary outcome measures Adverse reactions including gastrointestinal, skin, psychiatric and nervous system issues were collected from the allergy section of each patient’s medical record. Sex differences in the risk of adverse reactions due to prescribed opioids were modelled using logistic regression adjusted for age, body mass index, race and ethnicity. Results From 8457 participants (of which 449 (5.3%) reported adverse reactions), more women (6.5%) than men (3.4%) reported adverse reactions to at least one opioid (OR (95% CI)=2.3 (1.8 to 2.8), p<0.001). Women were more likely to report adverse reactions to tramadol (OR (95% CI)=2.8 (1.8 to 4.4), p<0.001) and oxycodone (OR (95% CI)=2.2 (1.7 to 2.9), p<0.001). Women were more likely to report gastrointestinal (OR (95% CI)=3.1 (2.3 to 4.3), p<0.001), skin (OR (95% CI)=2.1 (1.4 to 3.3), p=0.001) and nervous system issues (OR (95% CI)=2.3 (1.3 to 4.2), p=0.004). Conclusions These findings support the importance of sex as a biological variable to be factored into pain management studies.
Outcomes among patients with COVID-19 and asthma: A systematic review and meta-analysis
Sitek, Andrea , Ade, Justine M. , Divekar, Rohit , Pitlick, Mitchell M. , Joshi, Avni Y. , Sitek, Andrea N, Divekar, Rohit D, Chiarella, Sergio E. , Iyer, Vivek , Wang, Zhen

Mayo Clinic

Allergy and Asthma Proceedings | June 30, 2021 | Volume: 42 | Issue: 4 | Pages: 267-273

10.2500/aap.2021.42.210041 | PMID 34187619 Get It

Background: It remains unclear if asthma is a risk factor associated with worse outcomes among patients with coronavirus disease 2019 (COVID-19). Methods: We performed a comprehensive database search for studies published from January 1, 2019, to October 2, 2020. We included studies that evaluated outcomes among patients with COVID-19 and underlying asthma. Outcomes of interest included the need for hospitalization, length of hospitalization, intensive care unit (ICU) admission, and death. The meta-analysis was conducted by using random-effects methodology. Results: A total of 389 studies were identified through data base searches. After abstract and full-text screening, 16 observational studies with 92,275 patients were included in the analysis. Of the 16 studies, 15 were retrospective and 1 was a prospective cohort study. The average age was 39.6 years, with 48% female patients. Six of the studies included pediatric patients, and one of these studies only evaluated pediatric patients. One study only evaluated pregnant patients. Among patients with COVID-19, the presence of asthma was not associated with any significant increase in risk of hospitalization (odds ratio [OR] 1.46 [95% confidence interval {CI}, 0.29-7.28]), length of hospitalization (1.59 days [‐0.55 to 3.74]), ICU admission (OR 1.65 [95% CI, 0.56-4.17]), or death (OR 0.73 [95% CI, 0.38-1.40]). The overall risk of bias of the included studies was high. Conclusion: Among the patients with COVID-19, asthma did not seem to significantly increase the risk of hospitalization, length of hospitalization, ICU admission, or death.
NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer
Yuan, Yuan , Gao, Huanyao , Zhuang, Yongxian , Wei, Lixuan , Yu, Jia , Zhang, Zhe , Zhang, Lili , Wang, Liewei

Mayo Clinic

Therapeutic Advances in Medical Oncology | June 30, 2021 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/17588359211027836 | PMID 34276814 Get It

Background: Trastuzumab (Herceptin) is the key systemic therapy for HER2-positive breast cancer. However, the initial response rate is limited to approximately 50% in patients. Moreover, most patients, especially at an advanced stage, eventually develop acquired resistance. Understanding the mechanisms of trastuzumab resistance is crucial for achieving better treatment outcome in this group of patients. Methods: A trastuzumab-resistant (TR) cell line was developed using the BT474 HER2-positive breast cancer cell line. Whole-transcriptome expression array was performed and the TR-related gene NDUFA4L2 was identified by differential expression analysis between BT474 and BT474-TR. Mitochondrial localization of NDUFA4L2 was confirmed by immunofluorescence and western blotting using mitochondrial fractionation. Mitochondrial function and energy metabolism were evaluated using Seahorse, ATP production, and lactate production assays, and cellular reactive oxygen species (ROS) levels were determined using DCFDA. NDUFA4L2 expression in patients was evaluated by immunohistochemistry, and relapse-free survival was analyzed using the Kaplan–Meier method. Results: NDUFA4L2 was highly expressed in the TR HER2-positive breast cancer cell line. High expression level of NDUFA4L2 was associated with shorter relapse-free intervals in trastuzumab-treated HER2-positive breast cancer patients. Overexpression of NDUFA4L2 enhanced Warburg effects, enhanced aerobic glycolysis, reduced oxygen consumption, and lowered ROS production. Mechanistically, overexpression of NDUFA4L2 facilitated mitochondrial relocalization of HER2 and suppressed ROS production, thus rendering cancer cells more resistant to trastuzumab treatment. Conclusions: We identified NDUFA4L2 as a new biomarker and potential therapeutic target for TR HER2-positive breast cancer.
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate
Zhao, Jinge , Sun, Guangxi , Dai, Jindong, Chen, Junru , Zhang, Mengni , Ni, Yuchao , Shen, Pengfei , Zhao, Xiaochen , Zhang, Bei , Pan, Xiuyi , Yin, Xiaoxue , Liang, Jiayu, Wang, Zhipeng , Liao, Banghua , Liu, Zhenhua , Armstrong, Cameron M. , Chen, Ni , Zeng, Hao , Wang, Zhipeng , Zeng, Hao , Chen, Junru , Wang, Zhipeng , Zhu, Sha , Zhang, Haoran , Nie, Ling , Zhang, Xingming , Zhu, Xudong , Gao, Allen C , Huang, Haojie

Mayo Clinic

BJU International | June 29, 2021 | Volume: 129 | Issue: 3 | Pages: 345-355

10.1111/bju.15530 | PMID 34185954 Get It

Objectives To investigate the genetic alterations of patients with prostate cancer (PCa) with and without intraductal carcinoma of the prostate (IDC‐P). Patients and Methods We performed targeted sequencing of plasma cell‐free DNA on 161 patients with prostate adenocarcinoma (PAC) with IDC‐P and 84 without IDC‐P. Genomic alterations were compared between these two groups. The association between genetic alterations and patients’ survival outcomes was also explored. Results We identified that 29.8% (48/161) and 21.4% (18/84) of patients with and without IDC‐P harboured genomic alterations in DNA repair pathways, respectively ( P = 0.210). Pathogenic germline DNA repair alterations were frequently detected in IDC‐P carriers compared to IDC‐P non‐carriers (11.8% [19/161] vs 2.4% [two of 84], P = 0.024). Germline BReast CAncer type 2 susceptibility protein ( BRCA2 ) and somatic cyclin‐dependent kinase 12 ( CDK12 ) defects were specifically identified in IDC‐P carriers relative to PAC ( BRCA2 : 8.7% [14/161] vs 0% and CDK12 : 6.8% [11/161] vs 1.2% [one of 84]). Patients with IDC‐P had a distinct androgen receptor (AR) pathway alteration, characterised by an enrichment of nuclear receptor corepressor 2 ( NCOR2 ) mutations compared with patients with pure PAC (21.1% [34/161] vs 6.0% [five of 84], P = 0.004). Increased AR alterations were detected in patients harbouring tumours with an IDC‐P proportion of ≥10% vs those with an IDC‐P proportion of <10% (6.4% [five of 78] vs 18.1% [15/83], P = 0.045). For IDC‐P carriers, tumour protein p53 ( TP53 ) mutation was associated with shorter castration‐resistant‐free survival (median 10.9 vs 28.9 months, P = 0.026), and BRCA2 alteration was related to rapid prostate‐specific antigen progression for those receiving abiraterone treatment (median 9.1 vs 11.9 months, P = 0.036). Conclusion Our findings provide genomic evidence explaining the aggressive phenotype of tumours with IDC‐P, highlighting the potential therapeutic strategies for this patient population.
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes
Doran, Graeme, Cheung, Tak-Hong, Yim, So‐Fan, Yu, Mei‐Yung, Thorner, Aaron R. , Pedamallu, Chandra Sekhar , Lau, Kei-Man, Ducar, Matthew D. , Wong, Raymond R.Y., Wang, Vivian W., Nag, Anwesha , Wollison, Bruce M. , Dalgarno, Audrey, Lee, Jacqueline Ho Sze , Yeung, Suet-Ying, Wong, Lo , Leung, Shuk-On A., Mu, Yi , Mok, Samuel C. , Crum, Christopher P. , Chiu, Rossa W. K. , Berkowitz, Ross S. , Wong, Yick‐Fu, Thorner, Aaron R , Ducar, Matthew D , Lee, Jacqueline H S , Mok, Samuel C , Chung, Tony K.H. , Yim, So Fan, Worley, Michael J. , Elias, Kevin M. , Ojesina, Akinyemi I. , Yeung, Suet Ying, Horowitz, Neil S. , Davis, Michelle , Leung, Shuk On Annie , Chan, Paul K.S. , Lawrence, Michael S.

Mayo Clinic

Cancers | June 28, 2021 | Volume: 13 | Issue: 13 | Pages: 3218

10.3390/cancers13133218 | PMID 34203201 Get It

Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women’s cancer.
Association of vitamin D deficiency with COVID‐19 infection severity: Systematic review and meta‐analysis
Joshi, Avni Y. , Leopold, Kaitlin , Christensen, Stephanie , Nayfeh, Tarek , Mohammed, Khaled , Creo, Ana L. , Tebben, Peter J. , Kumar, Seema , Joshi, Avni, Jackson, Sarah, Creo, Ana , Tebben, Peter, Kumar, Seema , Nayfeh, Tarek , Tebben, Peter , Wang, Zhen , Jackson, Sarah

Mayo Clinic

Clinical Endocrinology | June 23, 2021 | Volume: 96 | Issue: 3 | Pages: 281-287

10.1111/cen.14540 | PMID 34160843 Get It

AbstractBackgroundWe sought to evaluate the association between vitamin D deficiency and the severity of coronavirus disease 2019 (COVID‐19) infection.MethodsMultiple databases from 1 January 2019 to 3 December 2020 were searched for observational studies evaluating the association between vitamin D deficiency and severity of COVID‐19 infection. Independent reviewers selected studies and extracted data for the review. The main outcomes of interest were mortality, hospital admission, length of hospital stay and intensive care unit admission.ResultsSeventeen observational studies with 2756 patients were included in the analyses. Vitamin D deficiency was associated with significantly higher mortality (odds ratio [OR]: 2.47, 95% confidence interval [CI]: 1.50–4.05; 12 studies; hazard ratio [HR]: 4.11, 95% CI: 2.40–7.04; 3 studies), higher rates of hospital admissions (OR: 2.18, 95% CI: 1.48–3.21; 3 studies) and longer hospital stays (0.52 days; 95% CI: 0.25–0.80; 2 studies) as compared to nonvitamin D deficient status. Subgroup analyses based on different cut‐offs for defining vitamin D deficiency, study geographic locations and latitude also showed similar trends.ConclusionsVitamin D deficiency is associated with greater severity of COVID‐19 infection. Further studies are warranted to determine if vitamin D supplementation can decrease the severity of COVID‐19.
MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression
Huang, Zhenlin , Tang, Bo , Yang, Yinhui , Yang, Zhaogang , Shi, Lei , Bai, Yang , Yan, Binyuan , Karnes, R. Jeffrey , Jiménez, Rafael E. , Wang, Liguo , Wei, Qiang , Yang, Jinjian , Xu, Wanhai , Jia, Zhankui , Jimenez, Rafael, Wang, Liguo , Huang, Rui , Yan, Binyuan , Zhang, Jun , Huang, Haojie

Mayo Clinic

Cancer Research | June 22, 2021 | Volume: 81 | Issue: 17 | Pages: 4471-4484

10.1158/0008-5472.can-20-4194 | PMID 34158377 Get It

Abstract Androgen receptor (AR) is a major survival factor for prostate cancer. Inflammation is implicated in many cancer types, including prostate cancer. Activation of MAP3K7 (also termed TAK1) and downstream IκB kinase β (IKKβ) by proinflammatory cytokines such as TNFα stimulates NF-κB survival pathways. Paradoxically, MAP3K7 is often deleted in human prostate cancer. Here, we demonstrate that AR protein expression is lower in inflammatory tumor areas compared with non-inflammatory tissues in patients with prostate cancer. Map3k7 knockout increased AR protein levels and activity in the mouse prostate, and MAP3K7 and AR protein levels were inversely correlated in prostate cancer patient specimens. TNFα treatment increased AR protein ubiquitination and proteasomal degradation. Mechanistically, activation of IKKβ by TNFα induced phosphorylation and TRCP1/2 E3 ligase–mediated polyubiquitination and degradation of AR protein. TNFα suppressed prostate cancer proliferation, which could be rescued by blockade of AR degradation. These findings reveal a previously unrecognized tumor suppressive function of the inflammation-activated MAP3K7–IKKβ axis in degrading AR protein. Moreover, they suggest that aberrant elevation of AR protein could be a prognostic biomarker and therapeutic target for MAP3K7-deficient prostate cancer. Significance: This study identifies that MAP3K7–IKKβ signaling plays a tumor-suppressive role in prostate cancer by degrading AR, revealing potential prognostic and therapeutic strategies for MAP3K7-deficient tumors.
Rare Copy Number Variants (CNVs) and Breast Cancer Risk
Dorling, Leila , Bola, Manjeet, Wang, Qin , Andrulis, Irene L. , Antonenkova, Natalia, Aronson, Kristan J. , Freeman, Laura Beane, Beckmann, Matthias W. , Bojeson, Stig, Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , Collaborators, NBCS, Collée, J. Margriet, Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, Hahen, Eric, Haiman, Christopher A. , Hoppe, Reine, Investigators, ACTB, Investigators, kConFab, Jager, Agnes , Johnson, Nichola , Keeman, Renske , Ko, Yon‐Dschun, Kosma, Veli‐Matti , Kristensen, Vessela N. , Kubelka‐Sabit, Katerina , Kurian, Alison, Larson, Nicole L. , Linet, Martha S. , Łukomska, Alicja, Mannermaa, Arto , Mavroudis, Dimitrios, Park‐Simon, Tjoung‐Won , Peterlongo, Paolo , Plaseska-Karanfilska, Dijana, Sawyer, Elinor J. , Schmutzler, Rita K., Shibli, Rana , Soucy, Penny, Tomlinson, Ian , Vachon, Celine M. , Wendt, Camilla, Yang, Xiaohong R. , Easton, Douglas F. , Peterlongo, Paolo , Evans, D Gareth , Chenevix-Trench, Georgia , Sawyer, Elinor J , Dennis, Joe , Tyrer, Jonathan P. , Walker, Logan C. , Michailidou, Kyriaki , Ahearn, Thomas U. , Anton‐Culver, Hoda , Arndt, Volker , Behrens, Sabine , Benı́tez, Javier , Bermisheva, Marina , Bojesen, Stig E. , Brenner, Hermann , Castelao, Jose E. , Clarke, Christine L. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Devilee, Peter , Dörk, Thilo , Dossus, Laure , Eliassen, A. Heather , Eriksson, Mikael , Figueroa, Jonine D. , Fletcher, Olivia , Fritschi, Lin , Gabrielson, Marike , Gago-Domínguez, Manuela , García‐Closas, Montserrat , Giles, Graham G. , González‐Neira, Anna , Guénel, Pascal , Hall, Per N , Hollestelle, Antoinette , Hoppe, Reiner , Hopper, John L. , Howell, Anthony , Jakubowska, Anna , John, Esther M. , Jones, Michael E. , Jung, Audrey , Kaaks, Rudolf , Хуснутдинова, Э. К. , Kitahara, Cari M. , Koutros, Stella , Kraft, Peter , Lambrechts, Diether , Manoukian, Siranoush , Margolin, Sara , Milne, Roger L. , Muranen, Taru , Murphy, Rachel A. , Nevanlinna, Heli , Olson, Janet E. , Olsson, Håkan , Perou, Charles M. , Pylkäs, Katri , Rennert, Gad , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Smeets, Ann , Southey, Melissa C. , Swerdlow, Anthony J. , Tamimi, Rulla M. , Taylor, Jack A. , Teras, Lauren R. , Terry, Mary Beth , Troester, Melissa A. , Truong, Thérèse , Vachon, Celine M. , Wendt, Camilla, Winqvist, Robert , Wolk, Alicja , Zheng, Wei , Ziogas, Argyrios , Simard, Jacques , Dunning, Alison M. , Pharoah, Paul D.P.

Mayo Clinic

No container title available | June 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-602209/v1 Get It

Abstract BackgroundCopy number variants (CNVs) are pervasive in the human genome but potential disease associations with rare CNVs have not been comprehensively assessed in large datasets. We analysed rare CNVs in genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data.ResultsGene burden tests detected the strongest association for deletions in BRCA1 (P= 3.7E-18). Nine other genes were associated with a p-value < 0.01 including known susceptibility genes CHEK2 (P= 0.0008), ATM (P= 0.002) and BRCA2 (P= 0.008). Outside the known genes we detected associations with p-values < 0.001 for either overall or subtype-specific breast cancer at nine deletion regions and four duplication regions. Three of the deletion regions were in established common susceptibility loci.ConclusionsThis is the first genome-wide analysis of rare CNVs in a large breast cancer case-control dataset. We detected associations with exonic deletions in established breast cancer susceptibility genes. We also detected suggestive associations with non-coding CNVs in known and novel loci with large effects sizes. Larger sample sizes will be required to reach robust levels of statistical significance.
Re-Evaluate Fusion Genes in Prostate Cancer
Wei, Ting , Ji, Lu , Ma, Tao , Kocher, Jean-Pierre A., Wang, Liguo , Wang, Liguo , Wei, Ting , Huang, Haojie

Mayo Clinic

Cancer Informatics | June 22, 2021 | Volume: 20 | Issue: No issue available | Pages: No page available

10.1177/11769351211027592 | PMID 34234399 Get It

Background: Thousands of gene fusions have been reported in prostate cancer, but their authenticity, incidence, and tumor specificity have not been thoroughly evaluated, nor have their genomic characteristics been carefully explored. Methods: We developed FusionVet to dedicatedly validate known fusion genes using RNA-seq alignments. Using FusionVet, we re-assessed 2727 gene fusions reported from 36 studies using the RNA-seq data generated by The Cancer Genome Atlas (TCGA). We also explored their genomic characteristics and interrogated the transcriptomic and DNA methylomic consequences of the E26 transformation-specific (ETS) fusions. Results: We found that nearly two-thirds of reported fusions are intra-chromosomal, and 80% of them were formed between 2 protein-coding genes. Although most (76%) genes were fused to only 1 partner, we observed many fusion hub genes that have multiple fusion partners, including ETS family genes, androgen receptor signaling pathway genes, tumor suppressor genes, and proto-oncogenes. More than 90% of the reported fusions cannot be validated by TCGA RNA-seq data. For those fusions that can be validated, 5% were detected from tumor and normal samples with similar frequencies, and only 4% (120 fusions) were tumor-specific. The occurrences of ERG, ETV1, and ETV4 fusions were mutually exclusive, and their fusion statuses were tightly associated with overexpressions. Besides, we found ERG fusions were significantly co-occurred with PTEN deletion but mutually exclusive with common genomic alterations such as SPOP mutation and FOXA1 mutation. Conclusions: Most of the reported fusion genes cannot be validated by TCGA samples. The ETS family and androgen response genes were significantly enriched in prostate cancer–specific fusion genes. Transcription activity was significantly repressed, and the DNA methylation was significantly increased in samples carrying ERG fusion.